leadf
logo-loader
viewOragenics Inc

Oragenics making 'great progress' enrolling patients in oral mucositis clinical trial

Oragenics (NYSE:OGEN) CEO Alan Joslyn caught up with Proactive at the BIO Investor Forum in San Francisco. 

Joslyn says Oragenics is making 'great progress' enrolling patients in oral mucositis clinical trial. Oral mucositis is a painful side effect in patients who are receiving chemotherapy in head and neck cancers.

Quick facts: Oragenics Inc

Price: 0.58 USD

NYSE:OGEN
Market: NYSE
Market Cap: $35.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Trident Royalties is 'all about diversification unlike majority of its peers'

Proactive analyst Ryan Long focuses on Trident Royalties (LON:TRR) a newly AIM-listed diversified mining royalty and streaming business. The company aims to provide investors with exposure to a broad range of development and cash-generating mining assets across the base metal, precious metal,...

44 minutes ago

2 min read